연구개발

글로벌 유전자·세포치료제 개발을 선도하는 바이오 혁신기업

핵심기술

Genetically modified MSCs are supplied in a frozen, allogeneic formulation in a large quantities.

  • Wound/tumor trophic MSCs
  • MSCs/genes act as bioreactors in vivo
  • One-time introduction of multiple genes for MCB
  • Equipped with a safety gene for controlling SAE
  • Overcoming the limitation of in vivo delivery of gene therapy
  • First-in-Class
  • Allogenic, Frozen, Off-the-Shelf
  • Easy scale-up of Master Cell Bank
  • A large quantity of Homogeneous Cells